You are in: eMedicine Specialties > Infectious Diseases > MEDICAL TOPICS ChancroidArticle Last Updated: May 12, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Alexandre F Migala, DO, Staff Physician, Department of Emergency Medicine, Denton Regional Medical Center Alexandre F Migala is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Osteopathic Association, Association of Military Osteopathic Physicians and Surgeons, and Texas Medical Association Coauthor(s): Gregory Shipkey, MD, Consulting Staff, Department of Emergency Medicine, MCH Medical Center, Odessa, Texas Editors: Larry I Lutwick, MD, Professor of Medicine, State University of New York, Downstate Medical School; Director, Infectious Diseases, Veterans Affairs New York Harbor Health Care System, Brooklyn Campus; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Charles V Sanders, MD, Edgar Hull Professor and Chairman, Department of Internal Medicine, Professor of Microbiology, Immunology and Parasitology, Louisiana State University School of Medicine at New Orleans; Medical Director, Medicine Hospital Center, Charity Hospital and Medical Center of Louisiana at New Orleans; Consulting Staff, Ochsner Medical Center; Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital; Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital Author and Editor Disclosure Synonyms and related keywords: sexually transmitted diseases, STD, genital ulcers, inguinal lymphadenopathy, Haemophilus ducreyi, H ducreyi, phagedenic chancroid, suppurative bubo, transient chancroid, dwarf chancroid, follicular chancroid, giant chancroid, pseudogranuloma inguinale INTRODUCTIONBackgroundChancroid is a sexually transmitted disease (STD) characterized by one or more painful genital ulcers usually accompanied by painful inguinal lymphadenopathy. The infection, while worldwide in distribution, generally is uncommon in industrialized countries; however, difficulty in definitively diagnosing the infection may somewhat cloud the true incidence of this infection. PathophysiologyChancroid is caused by the small, gram-negative, facultative anaerobic bacillus Haemophilus ducreyi, which produces a cytocidal distending toxin that appears to be responsible for its toxic effects. Transmitted by direct contact, the organism has an incubation period from 1 day to 2 weeks, with a median time of 5-7 days. The disease typically begins as a small inflammatory papule at the site of inoculation; within days, the papule erodes to form an extremely painful deep ulceration. FrequencyUnited StatesThe incidence of chancroid has declined steadily from 1987 (when >5000 cases were reported to the Centers for Disease Control and Prevention [CDC]) to 1997 (when only 243 cases were reported involving a total of 19 different states). The disease is considered endemic in several large US cities, and 85% of the 243 cases reported in 1997 were confined to California, New York, Texas, and South Carolina. Epidemics of disease are associated with low socioeconomic status, poor hygiene, prostitution, and drug abuse. In 2003, only 54 cases were reported to the CDC, with 24 of these cases from South Carolina. The true incidence is difficult to determine and is likely largely underestimated because of the difficulties in culturing H ducreyi. InternationalWorldwide, the true incidence of chancroid may surpass that of syphilis. Extremely common in Africa, the Caribbean basin, and Southwest Asia, the disease is thought to be the most common cause of genital ulceration in Kenya, Gambia, and Zimbabwe. Mortality/Morbidity
RaceAlthough no proven racial predilection exists, chancroid is most commonly observed in nonwhite people. SexChancroid is most commonly observed in nonwhite men who are uncircumcised. Women represent only 10% of known cases because they are more likely to be asymptomatic carriers. Chancroid is more commonly identified in individuals of lower socioeconomic status, prostitutes and travellers from endemic areas. According to Benson and Hergenroeder, there have been no reported cases of chancroid among homosexual males, bisexuals or lesbian females. AgeAlthough it can affect people of any age, chancroid predominantly affects younger sexually active people. Females aged 15-19 years have the highest prevalence among women in the United States, followed by those aged 20-24 years. In males, the highest prevalence is in those aged 20-24 years. CLINICALHistory
Physical
CausesChancroid is an STD resulting from direct contact with H ducreyi. Risk factors include residing in an endemic area, lower socioeconomic status, prostitution, and drug abuse. DIFFERENTIALSHerpes Simplex Syphilis
|
| Drug Name | Azithromycin (Zithromax) |
|---|---|
| Description | Treats mild-to-moderate microbial infections. |
| Adult Dose | 1 g PO single dose |
| Pediatric Dose | <6 months: Not established >6 months: 10 mg/kg PO single dose; not to exceed 500 mg/d |
| Contraindications | Documented hypersensitivity; hepatic impairment; concomitant administration with pimozide |
| Interactions | May increase toxicity of theophylline, warfarin, and digoxin; effects are reduced with coadministration of aluminum and/or magnesium antacids; nephrotoxicity and neurotoxicity may occur when coadministered with cyclosporine |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Site reactions can occur with IV route; bacterial or fungal overgrowth may result with prolonged antibiotic use; may increase hepatic enzymes and cholestatic jaundice; caution in patients with impaired hepatic function, prolonged QT intervals, or pneumonia; caution in patients who are hospitalized, elderly, or debilitated |
| Drug Name | Ceftriaxone (Rocephin) |
|---|---|
| Description | Third-generation cephalosporin with broad-spectrum gram-negative activity. Lower efficacy against gram-positive organisms. Higher efficacy against resistant organisms. Arrests bacterial growth by binding to 1 or more penicillin-binding proteins. |
| Adult Dose | 250 mg IM single dose |
| Pediatric Dose | >7 days: 25-50 mg/kg/d IV/IM; not to exceed 125 mg/d Infants and children: 50-75 mg/kg/d IV/IM divided q12h; not to exceed 2 g/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase levels; coadministration with ethacrynic acid, furosemide, and aminoglycosides may increase nephrotoxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal impairment; caution in breastfeeding women and allergy to penicillin |
| Drug Name | Erythromycin (E.E.S., E-Mycin, Eryc, Ery-Tab, Erythrocin) |
|---|---|
| Description | Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. For treatment of staphylococcal and streptococcal infections. |
| Adult Dose | 500 mg PO qid for 7 d |
| Pediatric Dose | 30-50 mg/kg/d (15-25 mg/lb/d) PO divided q6-8h; double dose for severe infection |
| Contraindications | Documented hypersensitivity; hepatic impairment |
| Interactions | Coadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin increases risk of rhabdomyolysis |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Caution in liver disease; estolate formulation may cause cholestatic jaundice; GI adverse effects are common (administer pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur |
| Drug Name | Ciprofloxacin (Cipro) |
|---|---|
| Description | Fluoroquinolone with activity against pseudomonads, streptococci, MRSA, Staphylococcus epidermidis, and most gram-negative organisms, but no activity against anaerobes. Inhibits bacterial DNA synthesis and, consequently, growth. |
| Adult Dose | 500 mg PO bid for 3 d |
| Pediatric Dose | <18 years: Not recommended >18 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Antacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; ciprofloxacin reduces therapeutic effects of phenytoin; probenecid may increase ciprofloxacin serum concentrations; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | In prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy |
Article Last Updated: May 12, 2006